Loading clinical trials...
Loading clinical trials...
Explorative Proteomics to Ease the Diagnosis of Pediatric Neuroborreliosis
This study aims to use proteomic analysis to diagnose Lyme Neuroborreliosis (LNB) in children. Pediatric patients with suspected LNB will be enrolled, and their blood samples will be collected for proteomic analyses. Mass spectrometry will be used to compare protein profiles of LNB-positive and LNB-negative patients. The data will be analyzed by bioinformaticians. The expected impact is to establish a non-invasive, reliable method for early LNB diagnosis to improve patient outcomes.
Objective: The primary objective of this study is to investigate the utility of proteomic analysis in diagnosing lyme neuroborreliosis (LNB) in children. By identifying specific protein markers associated with LNB (proteomics), the investigators aim to enhance early detection and improve patient outcomes. Methods: Participant Recruitment: The investigators will enroll pediatric patients (aged 1 month to 17 years) presenting with suspected LNB. Informed consent will be obtained from parents or legal guardians. Sample Collection: Peripheral blood samples will be collected from each participant in EDTA tubes. Samples will be processed to carry out proteomic analyses. Proteomic Analysis: Mass spectrometry will be employed to compare protein profiles between LNB-positive and LNB-negative patients. Data Analysis and Presentations: Protein profiles will be analysed by trained bioinformaticians and mainly presented in volcano plots and heat maps. Outcome Measures: Unique proteomic profiles of children with LNB. Expected Impact: This study aims to establish a non-invasive and reliable method for diagnosing LNB in children. Early identification will facilitate timely treatment and prevent complications associated with LNB.
Age
0 - 17 years
Sex
ALL
Healthy Volunteers
No
Rigshospitalet, Department of Children and Adolescents
Copenhagen, Denmark
Start Date
October 17, 2019
Primary Completion Date
October 10, 2023
Completion Date
December 10, 2024
Last Updated
September 3, 2024
106
ACTUAL participants
Proteomics
DIAGNOSTIC_TEST
Lead Sponsor
Rigshospitalet, Denmark
Collaborators
NCT04876131
NCT03781700
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions